FDA Approves First Treatment to Reduce Death Risk in Niemann-Pick C

Lembaz is the first FDA-approved therapy shown to lower the risk of death in infantile-onset Niemann-Pick disease type C.

Updated on Nov. 17, 2026 in Alzheimer’s

Bold flat-color editorial illustration of a single amber vial beside a long slender needle form on a pale field, evoking a rare-disease treatment approval.
The FDA approved Lembaz, the first therapy shown to lower the risk of death in infantile-onset Niemann-Pick disease type C. AI Illustration. Upload story photo >

Live Poll

Do you trust the FDA to approve safe, effective new medicines?

The FDA approved Lembaz (adrabetadex) injection for infantile-onset Niemann-Pick disease type C, a rare inherited lysosomal storage disorder. The approval was granted to Mandos, LLC, a subsidiary of Beren Therapeutics, PBC.

Why it matters

Two therapies were previously approved for this disease, and neither has been shown to reduce the risk of death, making Lembaz a distinct option for affected patients. The approval reflects FDA review of survival data across three clinical studies and an expanded access program.

The FDA reviewed survival data for 36 patients across three clinical studies and an expanded access program, finding a 55% reduction in risk of death versus a matched external control group. Median survival was 8.5 years for treated patients compared with 4.9 years for controls, though the small sample size and reliance on an external comparator leave the estimate's precision unclear.

The players

Mandos, LLC

Mandos, LLC is a subsidiary of Beren Therapeutics that received FDA approval for Lembaz.

Beren Therapeutics, PBC

Beren Therapeutics, PBC is the parent company of Mandos, LLC, the approval holder for Lembaz.

The details

Lembaz is given as an intrathecal injection directly into the spinal canal by a trained healthcare provider every two weeks. It is approved for adult and pediatric patients weighing at least 7 kg whose neurological symptoms began before age 6. The most common side effects include hearing, balance and coordination problems, fatigue, vomiting, and headache, and the drug carries a boxed warning for hearing impairment, including permanent hearing loss.

Timeline

  1. November 17, 2026: FDA approves Lembaz for infantile-onset Niemann-Pick disease type C.

Health Landscape

Lembaz marks the first FDA-approved therapy for Niemann-Pick disease type C shown to reduce mortality, departing from the two earlier approvals that did not demonstrate a survival benefit. The approval adds a survival-focused option to a disease area where treatment options have so far addressed symptoms rather than outcomes.

Families of children with infantile-onset Niemann-Pick disease type C may now have a treatment option shown to reduce the risk of death, which is delivered by intrathecal injection every two weeks. Patients receiving Lembaz will need regular monitoring for hearing problems, given the boxed warning for hearing impairment.

The takeaway

Lembaz shows that a therapy for a rare inherited disease can be evaluated for survival benefit even from small patient groups, though its boxed hearing warning and biweekly spinal injections make ongoing monitoring a central part of care.

Further reading

Explore more in Alzheimer’s coverage for related neurological disease context.

Live Poll

Do you trust the FDA to approve safe, effective new medicines?